ESTRO 2024 - Abstract Book

S2232

Clinical - Upper GI

ESTRO 2024

Keywords: Bile duct cancer, radiotherapy, nomogram

2178

Digital Poster

Role of ablative regimen and prior chemotherapy in liver metastases treated with SBRT

Marianna Valzano 1 , Marco Banini 1 , Mauro Loi 1 , Pierluigi Bonomo 1 , Gabriele Simontacchi 1 , Alessandra Galardi 1 , Carlotta Becherini 1 , Daniela Greto 1 , Erika Scoccimarro 1 , Giulio Francolini 1 , Isacco Desideri 1 , Monica Mangoni 1 , Vanessa Di Cataldo 1 , Viola Salvestrini 1 , Chiara Mattioli 1 , Lucia Angelini 1 , Luisa Caprara 1 , Margherita Zani 2 , Livia Marrazzo 2 , Laura Masi 3 , Raffaella Doro 3 , Lorenzo Livi 1 1 Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology, Florence, Italy. 2 Azienda Ospedaliero Universitaria Careggi, University of Florence, Medical Physics Unit, Florence, Italy. 3 Istituto Fiorentino di Cura e Assistenza (IFCA),, CyberKnife Center, Florence, Italy

Purpose/Objective:

Stereotactic Body Radiation Therapy (SBRT) is one of the local therapeutic options in the ablative treatment of liver metastases. This treatment can be applied in a wide heterogeneity of clinical scenarios, with reported great variability in terms of both, fractionation and technique. Therefore, the aim of this work is to evaluate the effects of SBRT to liver metastases in terms of outcomes and in clinical predictors associated with these outcomes.

Material/Methods:

All patients treated with SBRT for liver metastasis from 28/01/2019 to 31/07/2023 in our center for whom radiological follow-up of at least 3 months after the last course of SBRT was available, were included in our analysis. Patients were treated either with fiducial based real time tumor tracking using a robotic arm treatment platform (robotic arm radiotherapy, RRT) or with Volumetric Modulated Arc Therapy (VMAT), using a c-arm Linac aided by abdominal compression for the management of respiratory motion.

Clinical and treatment-related data were analyzed. Survival analysis was performed using the Kaplan-Meier, survival curve comparison was performed with Log-rank Test and Cox regression.

Local control (LC) and Progression Free Survival (PFS) were calculated for each treatment course.

Overall Survival (OS) was calculated for each patient, starting from the date of the first SBRT treatment.

Results: